细胞外囊泡介导的基因编辑治疗成年小鼠非综合征性进行性听力损失
本研究利用高通量微流控液滴电穿孔系统(μDES)将CRISPR-Cas9核糖核蛋白(RNP)复合物装载入细胞外囊泡(EV),装载效率较传统高压脉冲电穿孔提升10倍、通量提升超1000倍。在Myo7aWT/Sh1小鼠模型中,经后半规管注射RNP-EV可降低Myo7aSh1信使RNA表达,并较未治疗耳和仅注射EV的小鼠表现出听力保护证据。
要点
- μDES以直流低压(最高60 V)实现RNP高效装载入EV,装载效率提升10倍、通量提升超1000倍。
- 在Myo7aWT/Sh1小鼠中,经后半规管注射RNP-EV降低耳蜗毛细胞Myo7aSh1 mRNA表达。
- 听觉脑脊液反应显示RNP-EV注射耳较未治疗耳和仅EV注射小鼠有听力保护证据。
核心结论
- μDES生产的RNP-EV有望作为基因编辑工具用于治疗进行性非综合征性听力损失。
研究设计与样本
- 研究为动物实验,使用Myo7aWT/Sh1小鼠模型模拟人类MYO7A相关DFNA11听力损失。
- 通过μDES将CRISPR-Cas9 RNP复合物装载入EV,并在4周龄Myo7aWT/Sh1小鼠经后半规管注射RNP-EV。
主要发现
- μDES较传统高压脉冲电穿孔将RNP装载入EV的效率提升10倍,处理通量提升超过1000倍。
- μDES通过直流低压(最高60 V)产生含EV和RNP的均匀微液滴,在蛋白和形态水平维持EV完整性。
- 在Myo7aWT/Sh1小鼠中,RNP-EV经后半规管注射后经横断面和全组织共聚焦成像证实递送至耳蜗毛细胞。
- 4周龄Myo7aWT/Sh1小鼠注射RNP-EV后Myo7aSh1信使RNA表达降低,听觉脑干反应显示较未治疗耳和仅注射EV的小鼠有听力保护证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical translation of gene therapy has been challenging in part because of the limitations of current delivery approaches. Herein, we report an efficient nonviral genome editor delivery approach using extracellular vesicles (EVs) carrying single-guide RNA (sgRNA): CRISPR-Cas9 ribonucleoprotein (RNP) complexes for in vivo gene therapy. By leveraging a high-throughput microfluidic droplet-based electroporation system (μDES), we achieved a 10-fold enhancement in loading efficiency and more than 1000-fold increase in processing throughput for loading RNP complexes into EVs compared with conventional high-voltage pulsed electroporation. μDES generated uniform microdroplets containing EVs and RNPs by applying direct current-controlled low voltage (up to 60 V) to transiently permeabilize membranes and enable efficient cargo encapsulation while maintaining EV integrity at both the protein and morphological levels. In the Myo7aWT/Sh1 mouse model of autosomal dominant progressive hearing loss, which may model MYO7A-associated DFNA11 hearing loss in humans, we demonstrated the effective delivery of RNPs by EVs into cochlear hair cells by cross-sectional and whole-mount confocal imaging. The injection of RNP-EVs via the posterior semicircular canal in 4-week-old Myo7aWT/Sh1 mice resulted in a reduction in Myo7aSh1 messenger RNA expression and evidence of hearing preservation, as measured by auditory brainstem responses, compared with untreated ears and EV only-injected mice. This study highlights the potential of μDES-produced RNP-EVs for gene editing as a treatment for progressive nonsyndromic hearing loss in patients.
引用
- Pan X, Huang P, Ali SS, et al. Extracellular vesicle-mediated gene editing for the treatment of nonsyndromic progressive hearing loss in adult mice. Sci Transl Med. 2025. PMID: 41223249. doi:10.1126/scitranslmed.adn3993
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。